"Leading makers of antiwrinkle drugs, breast implants and other appearance-related products are trying to derail a proposed tax on elective cosmetic surgery in the Senate's health-overhaul bill.
The proposed 5% levy -- dubbed the "Botax" after the antiwrinkle treatment product Botox -- would raise an estimated $5.8 billion over 10 years."
Some are opposed to it, including plastic surgeons and "companies in aesthetic treatments."
"Botox treatments are by far the most popular procedure, costing an average of $443 in 2008, according to the American Society for Aesthetic Plastic Surgery. The American Medical Association, which also opposes the tax, says it would be the first federal levy on a medical procedure."